Shuai Gong

Focus on designing and generating novel biomacromolecule conjugation for targeted cancer and immune therapy. 1) Developed antibody-biologic conjugates that combined advantages of antibody drug conjugates and biologics therapy through orthogonal conjugation and polymer chemistry. Also expanded techniques to targeted enzyme therapy and CRISPR/Cas9 gene editing. 2) Innovated immune therapy and nano-vaccine using bio-conjugation methodology. Offered access to the modulation of immune cells by artificial immune complexes, inspired by the immune system's own mechanism, performing efficient antigen presenting and biocompatibility to primary immune cell. 3) Collaborated with the Cancer Science Institute of Singapore on peptide drug development projects. Guided the peptide conjugation, maintaining harmonious and regular communication and presentation with team members

Supported CNS targeted therapeutic oligonucleotides (ASO and RNA) and antibody drug conjugates (ADC) development. 1) Optimized conjugation for enhanced biological response to the central nervous system in animal models. 2) Developed efficient modification and purification methods, increasing yield by 20% via click chemistry. 3) Collaborated with the LNP and animal study groups at Biogen to generate tissue-specific biologic drug and nanomedicine with improved therapeutic window.

Focus on designing and generating novel biomacromolecule conjugation for targeted cancer and immune therapy. • Developed antibody-biologic conjugates that combined advantages of antibody drug conjugates and biologics therapy through orthogonal conjugation chemistry and polymer chemistry. Also expanded techniques to targeted enzyme therapy and CRISPR/Cas9 gene editing. • Innovated immune therapy and nano-vaccine using bio-conjugation methodology. Offered access to the modulation of immune cells by artificial immune complexes, inspired by the immune system's own mechanism, performing efficient antigen presenting and biocompatibility to primary immune cell.